Ikarian Capital, LLC Bluebird Bio, Inc. Transaction History

Ikarian Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$3.14 - $8.22 $1.26 Million - $3.29 Million	-400,000 Reduced 49.22%	412,628 $1.31 Million
Q4 2022 Feb 14, 2023	BUY	$5.77 - $8.49 $2.02 Million - $2.97 Million	350,000 Added 75.65%	812,628 $5.62 Million
Q3 2022 Nov 14, 2022	BUY	$3.75 - $7.39 $1.73 Million - $3.42 Million	462,628 New	462,628 $2.93 Million
Q2 2022 Aug 12, 2022	SELL	$2.94 - $5.23 $899 - $1,600	-306 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$4.07 - $10.6 $77 - $201	19 Added 6.62%	306 $1,000
Q4 2021 Feb 14, 2022	BUY	$8.96 - $16.31 $2,571 - $4,680	287 New	287 $2,000
Q2 2021 Aug 16, 2021	SELL	$18.04 - $22.09 $5,069 - $6,207	-281 Closed	0 $0
Q4 2020 Feb 12, 2021	SELL	$27.5 - $37.92 $1.1 Million - $1.52 Million	-40,000 Reduced 99.3%	281 $12,000
Q3 2020 Nov 16, 2020	SELL	$34.44 - $43.75 $2.22 Million - $2.83 Million	-64,593 Reduced 61.59%	40,281 $2.17 Million
Q2 2020 Aug 14, 2020	BUY	$27.12 - $45.97 $2.67 Million - $4.52 Million	98,376 Added 1513.94%	104,874 $6.4 Million
Q1 2020 May 15, 2020	BUY	$26.16 - $63.5 $169,987 - $412,623	6,498 New	6,498 $299,000

150

63.4M

264K

428K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $708M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.